Excelsior Biopharma (6496) — Cash Flow Quality Index
Excelsior Biopharma (6496) has a Cash Flow Quality Index of -3.02x as of December 2023. Operating cash flow of NT$-25.78 Million is below net income of NT$8.54 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Excelsior Biopharma total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Excelsior Biopharma Cash Flow Quality Index (2017–2020)
Historical Cash Flow Quality Index for Excelsior Biopharma across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 6496 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Excelsior Biopharma (2017–2020)
Year-by-year earnings quality comparison for Excelsior Biopharma. For live market cap and the full company financial profile, see Excelsior Biopharma (6496) total market value.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2020 | 11.50x | NT$520.81 Million | NT$45.30 Million | ▲ +581.0% |
| 2019 | -2.39x | NT$-169.74 Million | NT$71.01 Million | ▼ -517.8% |
| 2018 | 0.57x | NT$126.92 Million | NT$221.83 Million | ▼ -54.2% |
| 2017 | 1.25x | NT$349.47 Million | NT$279.68 Million | — |